Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Hematology
Published in: BMC Hematology 1/2011

Open Access 01-12-2011 | Research article

Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data

Authors: R Andrew Moore, Helen Gaskell, Peter Rose, Jonathan Allan

Published in: BMC Hematology | Issue 1/2011

Login to get access

Abstract

Background

Recommendations given for intravenous iron treatment are typically not supported by a high level of evidence. This meta-analysis addressed this by summarising the available date from clinical trials of ferric carboxymaltose using clinical trial reports and published reports.

Methods

Clinical trial reports were supplemented by electronic literature searches comparing ferric carboxymaltose with active comparators or placebo. Various outcomes were sought for efficacy (attainment of normal haemoglobin (Hb), increase of Hb by a defined amount, for example), together with measures of harm, including serious adverse events and deaths.

Results

Fourteen studies were identified with 2,348 randomised patients exposed to ferric carboxymaltose, 832 to oral iron, 762 to placebo, and 384 to intravenous iron sucrose. Additional data were available from cohort studies. Intravenous ferric carboxymaltose was given up to the calculated iron deficit (up to 1,000 mg in one week) for iron deficiency anaemia secondary to chronic kidney disease, blood loss in obstetric and gynaecological conditions, gastrointestinal disease, and other conditions like heart failure. The most common comparator was oral iron, and trials lasted 1 to 24 weeks. Intravenous ferric carboxymaltose improved mean Hb, serum ferritin, and transferrin saturation levels; the mean end-of-trial increase over oral iron was, for Hb 4.8 (95% confidence interval 3.3 to 6.3) g/L, for ferritin 163 (153 to 173) μg/L, and for transferrin saturation 5.3% (3.7 to 6.8%). Ferric carboxymaltose was significantly better than comparator in achievement of target Hb increase (number needed to treat (NNT) 6.8; 5.3 to 9.7) and target Hb NNT (5.9; 4.7 to 8.1). Serious adverse events and deaths were similar in incidence in ferric carboxymaltose and comparators; rates of constipation, diarrhoea, and nausea or vomiting were lower than with oral iron.

Conclusions

This review examined the available trials of intravenous ferric carboxymaltose using details from published papers and unpublished clinical trial reports. It increases the evidence available to support recommendations given for intravenous iron treatment, but there are limited trial data comparing different intravenous iron preparations.
Appendix
Available only for authorised users
Literature
1.
de Benoist B, McLean E, Egli I, Cogswell M: Worldwide prevalence of anaemia 1993-2005. 2008, WHO Global Database on Anaemia, World Health Organisation
2.
Gaskell H, Derry S, Andrew Moore R, McQuay HJ: Prevalence of anaemia in older persons: systematic review. BMC Geriatr. 2008, 8: 1-10.1186/1471-2318-8-1.CrossRefPubMedPubMedCentral
3.
4.
Varney SJ, Guest JF: The annual cost of blood transfusions in the UK. Transfus Med. 2003, 13: 205-218. 10.1046/j.1365-3148.2003.00443.x.CrossRefPubMed
5.
Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR: Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010, 50: 753-765. 10.1111/j.1537-2995.2009.02518.x.CrossRefPubMed
6.
7.
McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002, 13: 928-1936.
8.
Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003, 41: 1933-1939. 10.1016/S0735-1097(03)00425-X.CrossRefPubMed
9.
Langston RD, Presley R, Flanders WD, McClellan WM: Renal insufficiency and anemia are independent risk factors for death among people with acute myocardial infarction. Kidney Int. 2003, 64: 1398-1405. 10.1046/j.1523-1755.2003.00200.x.CrossRefPubMed
10.
Patel KV, Longo DL, Ershler WB, Yu B, Semba RD, Ferrucci L, Guralnik JM: Haemoglobin concentration and the risk of death in older adults: differences by race/ethnicity in the NHANES III follow-up. Br J Haematol. 2009, 145: 514-523. 10.1111/j.1365-2141.2009.07659.x.CrossRefPubMedPubMedCentral
11.
Teng TH, Finn J, Hung J: Mild anaemia is associated with increased all-cause mortality in heart failure. Heart Lung Circ. 2010, 19: 31-37. 10.1016/j.hlc.2009.08.004.CrossRefPubMed
12.
Zoppini G, Targher G, Chonchol M, Negri C, Stoico V, Pichiri I, Lippi G, Muggeo M, Bonora E: Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis. 2010, 210: 575-580. 10.1016/j.atherosclerosis.2009.12.008.CrossRefPubMed
13.
Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007, 369: 381-388. 10.1016/S0140-6736(07)60194-9.CrossRefPubMed
14.
Shander A, Cappellini MD, Goodnough LT: Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang. 2009, 97: 185-197. 10.1111/j.1423-0410.2009.01207.x.CrossRefPubMed
15.
Ershler WB, Chen K, Reyes EB, Dubois R: Economic burden of patients with anemia in selected diseases. Value Health. 2005, 8: 629-638. 10.1111/j.1524-4733.2005.00058.x.CrossRefPubMed
16.
Pugh-Clarke K, Cooper L, Turner J, Fermin J: An evidence-based approach to anaemia management in predialysis chronic kidney disease. J Ren Care. 2009, 35 (Suppl 2): 29-31.CrossRefPubMed
17.
Besarab A, Hörl WH, Silverberg D: Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009, 14 (Suppl 1): 22-33.CrossRefPubMed
18.
Handelman GJ, Levin NW: Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev. 2008, 13: 393-404. 10.1007/s10741-008-9086-x.CrossRefPubMed
19.
Clark SF: Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol. 2009, 25: 122-128. 10.1097/MOG.0b013e32831ef1cd.CrossRefPubMed
20.
Kulnigg S, Gasche C: Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006, 24: 1507-1523. 10.1111/j.1365-2036.2006.03146.x.CrossRefPubMed
21.
Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008, 52: 897-906. 10.1053/j.ajkd.2008.05.033.CrossRefPubMed
22.
Macdougall IC: Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?. Curr Med Res Opin. 2010, 26: 473-482. 10.1185/03007990903512461.CrossRefPubMed
23.
Gisbert JP, Gomollón F: Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008, 103: 1299-1307. 10.1111/j.1572-0241.2008.01846.x.CrossRefPubMed
24.
Bailie GR, Clark JA, Lane CE, Lane PL: Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005, 20: 1443-1449. 10.1093/ndt/gfh820.CrossRefPubMed
25.
Kovesdy CP, Kalantar-Zadeh K: Iron therapy in chronic kidney disease: current controversies. J Ren Care. 2009, 35 (Suppl 2): 14-24.CrossRefPubMed
26.
Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989, 299: 157-158. 10.1136/bmj.299.6692.157.CrossRefPubMedPubMedCentral
27.
Tagboto S, Cropper L, Turner J, Pugh-Clarke K: The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Ren Care. 2009, 35: 18-23. 10.1111/j.1755-6686.2009.00075.x.CrossRefPubMed
28.
Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC: Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010, 303: 857-864. 10.1001/jama.2010.206.CrossRefPubMed
29.
30.
Lyseng-Williamson KA, Keating GM: Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009, 69: 739-756. 10.2165/00003495-200969060-00007.CrossRefPubMed
31.
Muñoz M, Breymann C, García-Erce JA, Gómez-Ramírez S, Comin J, Bisbe E: Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang. 2008, 94: 172-183. 10.1111/j.1423-0410.2007.01014.x.CrossRefPubMed
32.
Moore RA, Edwards JE, McQuay HJ: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol. 2002, 2: 6-10.1186/1471-2490-2-6.CrossRefPubMedPubMedCentral
33.
Moore RA, Derry S, Makinson GT, McQuay HJ: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005, 7: R644-665. 10.1186/ar1704.CrossRefPubMedPubMedCentral
34.
Moore RA, Derry S, McQuay HJ: Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Res Ther. 2008, 10: R53-10.1186/ar2422.CrossRefPubMedPubMedCentral
35.
Bailie GR, Mason NA, Valaoras TG: Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. 2010, 14: 47-54. 10.1111/j.1542-4758.2009.00409.x.CrossRefPubMed
36.
Funk F, Ryle P, Canclini C, Neiser S, Geisser P: The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010, 60: 345-353.PubMed
37.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.CrossRefPubMed
38.
L'Abbé KA, Detsky AS, O'Rourke K: Meta-analysis in clinical research. Ann Intern Med. 1987, 107: 224-233.CrossRefPubMed
39.
Morris JA, Gardner MJ: Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. Statistics with confidence: confidence intervals and statistical guidelines. Edited by: Gardner MJ, Altman DG. 1995, London: British Medical Journal, 50-63.
40.
McQuay HJ, Moore RA: Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997, 126: 712-720.CrossRefPubMed
41.
Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT: Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009, 49: 2719-2728. 10.1111/j.1537-2995.2009.02327.x.CrossRefPubMed
42.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009, 361: 2436-2448. 10.1056/NEJMoa0908355.CrossRefPubMed
43.
Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group: FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology. 2011,w
44.
Clinical Study Report 1VIT04004. Vifor Pharmaceuticals. Data on file: Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (VIT-45) Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease. 2007
45.
Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD: A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2010
46.
Clinical Study Report VIT-IV-CL-015. Vifor Pharmaceuticals. Data on file: A multicentre, controlled Phase III Study to Compare the Efficacy and Safety of VIT-45 and Venofer in the Treatment of Iron Deficiency Anaemia Associated with Chronic Renal Failure in Patients on Haemodialysis. 2005
47.
Clinical Study Report 1VIT04005. Vifor Pharmaceuticals. Data on file: Open Label Extrension Study Evaluating the Long Term safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT-45 in the Treatment of Anemia in Non-Dialysis Dependent (NDD) Chronic Kidney Disease (CKD). 2007
48.
Clinical Study Report 53214. Vifor Pharmaceuticals. Data on file: A multicentre, open-label, single-arm study to investigate the safety and efficacy of intravenous VIT-45 in haemodialysis patients with anaemia. 2004
49.
Covic A, Mircescu G: The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant. 2010, 25: 2722-2730. 10.1093/ndt/gfq069.CrossRefPubMedPubMedCentral
50.
Clinical Study Report VIT-IV-CL-009. Vifor Pharmaceuticals. Data on file: A Multicentre, Controlled, Phase III Study to Investigate the Safety and Efficacy of Intravenous Infusions of Vit-45 In Women Suffering from Post-Partum Anaemia. 2006
51.
Breymann C, Gliga F, Bejenariu C, Strizhova N: Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008, 101: 67-73. 10.1016/j.ijgo.2007.10.009.CrossRefPubMed
52.
Clinical Study Report 1VIT06011. Vifor Pharmaceuticals. Data on file: The Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients. 2007
53.
Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R: Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008, 199 (435): e1-7.PubMed
54.
Clinical Study Report 1VIT04002/1VIT04003. Vifor Pharmaceuticals. Data on file: Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (VIT-45) Versus Oral Iron in the Treatment of Iron Deficiency Anemia Secondary to Heavy Uterine Bleeding. 2006
55.
Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A: Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007, 110: 267-278. 10.1097/01.AOG.0000275286.03283.18.CrossRefPubMed
56.
Clinical Study Report VIT-IV-CL-03. Vifor Pharmaceuticals. Data on file: A multicentre, open-label, phase I/II, pharmacodynamic and safety study of VIT-45 given in multiple doses for up to 4 weeks to patients with moderate, stable iron deficiency anaemia secondary to a gastrointestinal disorder. 2004
57.
Clinical Study Report VIT-IV-CL-008. Vifor Pharmaceuticals. Data on file: A Multi-Centre, Randomised, Controlled, Phase III Study to Investigate the Safety and Efficacy of Intravenous Infusions of VIT-45 in Patients with Iron Deficiency Anaemia Secondary to Chronic Inflammatory Bowel Disease. 2005
58.
Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C: A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008, 103: 1182-1192. 10.1111/j.1572-0241.2007.01744.x.CrossRefPubMed
59.
Clinical Study Report 1VIT05006. Vifor Pharmaceuticals. Data on file: A Multicenter, Randomized, Blinded, Placebo-Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous VIT-45 in Patients with Iron Deficiency Anemia. 2006
60.
Clinical Study Report CARS 1. Vifor Pharmaceuticals. Data on file: A pilot randomised double-blind Controlled phase III study to comparethe efficacy and safety of Ferinject® and Venofer® versus standard therapy in patients with chronic heart failure, renal failure and iron deficiency (CARS I). 2008
61.
Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, Goodnough LT, Wolf M, Onken JE: Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anaemia and Impaired Renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant. 2010, 25: 2368-2375. 10.1093/ndt/gfq218.CrossRefPubMed
62.
63.
MacKenzie EL, Iwasaki K, Tsuji Y: Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008, 10: 997-1030. 10.1089/ars.2007.1893.CrossRefPubMedPubMedCentral
64.
Bleackley MR, Wong AY, Hudson DM, Wu CH, Macgillivray RT: Blood iron homeostasis: newly discovered proteins and iron imbalance. Transfus Med Rev. 2009, 23: 103-123. 10.1016/j.tmrv.2008.12.001.CrossRefPubMed
65.
Straube S, Derry S, Moore RA, McQuay HJ: Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford). 2010, 49: 706-15. 10.1093/rheumatology/kep432.CrossRef
66.
Lau JH, Gangji AS, Rabbat CG, Brimble KS: Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant. 2010, 25: 4002-4009. 10.1093/ndt/gfq330.CrossRefPubMed
67.
Qunibi WY: The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung. 2010, 60: 399-412.PubMed
68.
Knight TG, Ryan K, Schaefer CP, D'Sylva L, Durden ED: Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy. J Manag Care Pharm. 2010, 16: 605-15.PubMed
Metadata
Title
Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data
Authors
R Andrew Moore
Helen Gaskell
Peter Rose
Jonathan Allan
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Hematology / Issue 1/2011
Electronic ISSN: 2052-1839
DOI
https://doi.org/10.1186/1471-2326-11-4
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits